Olaparib launch date

Olaparib was first approved by the FDA and the European Union in December 2014. Health Canada approved it in 2016 Approved in April 2018, Olaparib (Olaparib) was launched in China in August 2018. Olaparib(Olaparib)is a poly (ADP-ribose) polymerase (PARP) inhibitor used to treat ovarian, breast, pancreatic, and prostate cancer.

Olaparib is a selective and potent inhibitor of the poly(ADP-ribose) polymerase (PARP) enzymes PARP1 and PARP2. PARPinhibitors represent a new class of anticancer therapies that work by exploiting defects in DNA repair in cancer cells with BRCA mutations and inducing cell death.

Olaparib is a cytotoxic and antineoplastic drug. Lynparza inhibits the growth of selected tumor cell lines in vitro and reduces tumor growth in mouse xenograft models of human cancer, both as monotherapy and after platinum-based chemotherapy. The drug exerts antitumor effects in cell lines and mouse tumor models with defects in BRCA1/2, ATM, or other genes involved in homologous recombination repair of DNA damage (HRR) and associated with platinum response. In preclinical models of cancer, olaparib has shown antitumor activity when used alone, in combination with chemotherapy drugs, or with radiation therapy. Olaparib can act as a chemical sensitizer to enhance the cytotoxicity of DNAdamaging chemotherapy agents such as alkylating agents and platinum-based drugs, and it can also act as a radiosensitizer by preventing PARP-mediated DNA repair. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to learn more about high-quality overseas drugs for you.